The Anti-Neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Anti-Neprilysin is an enzyme that breaks down natriuretic peptides which play a role in regulating blood pressure and sodium balance in the body. Inhibiting the breakdown of natriuretic peptides provides benefits in congestive heart failure and hypertension treatment. The major products in this market are racecadotril and sachet. Racecadotril is used for acute diarrhea in adults and children. Sachet containing powdered omapatrilat is administered orally for treating hypertension and heart failure.
The growth of the Anti-Neprilysin market is attributed to increasing prevalence of cardiovascular diseases globally. As per the World Health Organization (WHO), cardiovascular diseases are the number one cause of death globally, taking an estimated 17.9 million lives each year. Rising geriatric population is also susceptible to develop hypertension and heart failure which is further driving the market growth. Additionally, ongoing research and development for developing potent and selective neprilysin inhibitors to treat heart failure is expected to create lucrative opportunities for players in this market over the forecast period.
Strength: Three sentence explanation – The anti-Neprilysin market has strong growth prospects due to rising prevalence of heart failures and hypertension. Their mechanism of action that enhances the activity of natriuretic peptides to lower blood pressure provides clinical benefits. Several pipeline drugs offer improved efficacy and safety.
Weakness: Two weakness in three sentence explanation – High development costs and regulatory barriers negatively impact market growth. Side effects of anti-Neprilysin drugs such as hypotension, angioedema and renal impairment limits their adoption.
Opportunity: Two opportunity in three sentence explanation – Emerging economies provide lucrative opportunities owing to growing health expenditures. Combination therapies with other drug classes present opportunities to expand clinical applications.
Threats: Two threats two sentence explanation – Patent expiries of major drugs increases competition from generic versions. Alternate treatment options including device-based therapies pose challenge.
The global Anti-Neprilysin market is expected to witness high growth, exhibiting CAGR of 4.6% over the forecast period, due to increasing prevalence of heart failures and hypertension. The North American region dominated the global market in 2023, owing to growing elderly population and strong healthcare infrastructure.
Regional analysis Europe is projected to witness the highest CAGR of 5.2% during the forecast period. This is attributed to increasing investments for drug development projects by major players in the region.
Key players operating in the Anti-Neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd. BIOPROJET dominates the market and is exploring combination therapies to widen clinical applications of anti-Neprilysins.